Kardigan, Inc. (KARD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Kardigan, Inc. in 2026. The next earnings report is expected on September 2, 2026.
Next earnings date
02 Sep 2026
In 14 days
EPS estimate
-0.68
Revenue estimate
0
Past earnings
Latest earnings analysis
Kardigan, Inc. missed consensus on EPS, posting a loss of USD -4.61 versus an estimate of USD -0.6753, while revenue met expectations at USD 0. In the prior report, EPS was a loss of USD -1.4335 and revenue was USD 0, with no consensus comparisons provided.
No dividend history available.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Kardigan, Inc. (KARD) is scheduled to report earnings on September 2, 2026.
Kardigan, Inc. (KARD) last reported earnings on August 11, 2026.
Kardigan, Inc. (KARD) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.